Mind Medicine (MindMed) (NASDAQ: MNMD)
Mind Medicine (MindMed) Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Mind Medicine (MindMed) Company Info
Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.
News & Analysis
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today
Mind Medicine stock hasn't beaten the market over the last five years, but what comes next?
MindMed Reports Strong Q2 2025 Results
1 Reason to Buy MindMed (MNMD)
The U.S. public and the nation's politicians seem to be coming around to the idea of reforming psychedelic drug laws. Looser restrictions on research would help this company.
MindMed (MNMD) Q2 Net Loss Jumps 625%
Why Mind Medicine Gave Investors a Powerful Buzz in May
Why Mind Medicine Stock Vaulted More Than 8% Higher Today
Best Psychedelic Stocks to Buy in April 2025
Why Mind Medicine Stock Is Skyrocketing Today
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.